This study investigates pancreatic ductal adenocarcinoma. It looks at the use of endoscopic ultrasound (EUS) radiofrequency ablation (RFA) combined with standard chemotherapy before surgery.
The study evaluates the feasibility, tolerability, and treatment effects of combining EUS-RFA with chemotherapy. It focuses on how these treatments may impact the surgery process.
- Who can participate: Adults diagnosed with pancreatic ductal adenocarcinoma who have not had significant prior chemotherapy and can provide consent are eligible. Participants must meet certain health criteria.
- Study details: Participants will receive an investigational treatment combining EUS-RFA and chemotherapy before surgery. A placebo is not used in this study.